Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.

INTRODUCTION: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post hoc analysis assessed the efficacy of tofacitinib using pooled data from two phase 3 studies of patients with active PsA.
METHODS: Data were pooled from OPAL Broaden (NCT01877668) and OPAL Beyond (NCT01882439). Patients had active PsA and either an inadequate response (IR) to ≥ 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD) and were tumor necrosis factor inhibitor (TNFi)-naïve (OPAL Broaden), or had IR to ≥ 1 TNFi (OPAL Beyond). Pooled data included tofacitinib 5 or 10 mg twice daily (BID; to month 6) and placebo (to month 3; patients then switched to tofacitinib 5 or 10 mg BID). Patients also received one background csDMARD. Endpoints included American College of Rheumatology (ACR)20 response and change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at month 3 (primary endpoints), ACR50/70 response, HAQ-DI response (decrease from baseline ≥ 0.35) and improvements in painful and swollen joint counts, psoriasis, enthesitis and dactylitis to month 6.
RESULTS: A total of 710 patients were included (tofacitinib 5 mg BID: 238; tofacitinib 10 mg BID: 236; placebo: 236). Primary endpoints showed significant improvements at month 3 in patients receiving tofacitinib 5 or 10 mg BID vs. placebo. Significant improvements in HAQ-DI response, painful and swollen joints, psoriasis, enthesitis and dactylitis vs. placebo were observed for both tofacitinib doses at month 3. Efficacy was maintained to month 6 (final pooled time point).
CONCLUSIONS: In a pooled analysis of csDMARD-IR/TNFi-naïve and TNFi-IR patients, tofacitinib was superior to placebo at month 3 across four PsA domains: peripheral arthritis, psoriasis, enthesitis and dactylitis. TRIAL REGISTRATION: OPAL Broaden (NCT01877668); OPAL Beyond (NCT01882439). FUNDING: Pfizer Inc.

RCT Entities:   Population Interventions Outcomes

Introduction

Psoriatic arthritis (PsA) is a chronic inflammatory disease that can impact multiple domains, including peripheral arthritis, skin and nail psoriasis, enthesitis, dactylitis, and spondylitis [1]. PsA occurs in approximately 20–30% of patients with psoriasis [2-4], and can be associated with substantial healthcare costs, impairments in health-related quality of life, and work productivity [5-7].

Although there are efficacious treatments for PsA currently approved, not all patients achieve satisfactory disease control as evidenced by their failure to attain an American College of Rheumatology (ACR)20 response after 24 weeks in randomized clinical trials [8-13]. A number of studies report that over 50% of patients treated with tumor necrosis factor inhibitor (TNFi) therapy for up to 12 months fail to reach minimal disease activity [14-17]. Due to the inability of any approved medication to treat all patients effectively, approximately 50% of patients have been reported to switch, restart after a treatment gap, or discontinue therapy within the first year of treatment in the United States [18], strongly suggesting that there is a significant unmet need for new therapies with novel mechanisms of action for patients with PsA. Research into the proinflammatory mechanisms of the pathogenesis of PsA has resulted in the development of small molecule therapies for the treatment of PsA, including apremilast and tofacitinib [19].

Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. The safety and efficacy of tofacitinib 5 and 10 mg twice daily (BID) have been demonstrated in phase 3 trials of 6 and 12 months’ duration in patients with active PsA and an inadequate response (IR) to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or TNFi therapy [20-22]. Tofacitinib is also being investigated in an ongoing long-term extension (LTE) study in patients with PsA (NCT01976364).

Pooling data from clinical studies of patients with PsA offers a larger patient sample size for the analysis of disease manifestations that do not affect all patients with PsA, such as enthesitis, dactylitis, axial involvement, and current psoriasis, and yields more precise estimates for endpoints that assess these manifestations compared with the individual studies. This post hoc analysis reports the efficacy of tofacitinib using pooled data from the two pivotal phase 3 studies of patients with PsA.

Methods

Study Design

Data from baseline to month 6 were pooled from patients participating in the two phase 3 studies who had been randomized to tofacitinib 5 or 10 mg BID (for the duration of the study) or placebo.

The Oral Psoriatic Arthritis trial (OPAL) Broaden (A3921091; NCT01877668) was a 12-month, global, double-blind, double-dummy, placebo- and active-controlled parallel-group phase 3 study in TNFi-naïve adults with active PsA receiving one background csDMARD and with an IR to ≥ 1 csDMARD. Patients were randomized 2:2:2:1:1 to receive tofacitinib 5 mg BID, tofacitinib 10 mg BID, an active comparator (adalimumab 40 mg subcutaneously once every other week), placebo → tofacitinib 5 mg BID or placebo → tofacitinib 10 mg BID. Patients on placebo switched to tofacitinib at month 3 [20].

OPAL Beyond (A3921125; NCT01882439) was a 6-month, global, double-blind, placebo-controlled, parallel-group phase 3 study in adults with active PsA receiving one background csDMARD and with an IR to ≥ 1 TNFi. Patients were randomized 2:2:1:1 to receive tofacitinib 5 mg BID, tofacitinib 10 mg BID, placebo → tofacitinib 5 mg BID or placebo → tofacitinib 10 mg BID. Patients on placebo switched to tofacitinib at month 3 [21].

Both studies included identical efficacy assessments at the same time points up to month 6.

OPAL Broaden and OPAL Beyond were conducted in accordance with the Good Clinical Practice Guidelines of the International Conference on Harmonisation, the Declaration of Helsinki, and the local country regulations. The study protocols were approved by the institutional review board or the independent ethics committee at each site.

Efficacy Endpoints

Endpoints included the proportions of patients achieving ACR20 response at month 3 (primary endpoint in the individual studies) and at time points other than month 3; proportions of patients achieving ACR50 and ACR70 responses at all time points; proportions of patients achieving the minimal clinically important difference for Health Assessment Questionnaire-Disability Index (HAQ-DI; range, 0–3; higher scores indicate greater disability) response (decrease from baseline of ≥ 0.35) [23] in patients with baseline HAQ-DI ≥ 0.35; proportions of patients achieving Psoriasis Area and Severity Index (PASI)75 (≥ 75% improvement from baseline in PASI; range, 0.0–72.0; higher scores indicate more severe psoriasis) in patients with baseline body surface area (BSA; range, 0–100%; higher scores indicate greater BSA affected by psoriasis) ≥ 3% and PASI > 0; proportions of patients with resolution of enthesitis (Leeds Enthesitis Index [LEI] score of 0; range, 0–6; higher scores indicate more affected sites) in patients with baseline LEI > 0; proportions of patients with resolution of enthesitis (Spondyloarthritis Research Consortium of Canada [SPARCC] Enthesitis Index score of 0; range, 0–16; higher scores indicate more affected sites) in patients with baseline SPARCC Enthesitis Index > 0; proportions of patients with resolution of dactylitis (Dactylitis Severity Score [DSS] of 0; range, 0–60; higher scores indicate greater severity/more affected sites) in patients with baseline DSS > 0 and proportions of patients with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) response (BASDAI < 4 cm; range, 0–10 cm; higher scores indicate more severe ankylosing spondylitis disease activity, including worse symptoms of back pain) in patients with presence of spondylitis as determined by the investigator at screening and with baseline BASDAI ≥ 4 cm (imaging was not required to confirm the presence of spondylitis). Other endpoints included the changes from baseline in the following manifestations of PsA: HAQ-DI at month 3 (primary endpoint in the individual studies) and at time points other than month 3; painful/tender joint count (JC; out of 68 joints; range, 0–68; higher score indicates a greater number of painful joints); swollen JC (out of 66 joints; range, 0–66; higher score indicates a greater number of inflamed joints); Dermatology Life Quality Index (DLQI; range, 0–30; higher scores indicate greater impairment); LEI in patients with baseline LEI > 0; SPARCC Enthesitis Index in patients with baseline SPARCC Enthesitis Index > 0; DSS in patients with baseline DSS > 0; and BASDAI in patients with presence of spondylitis as determined by the investigator at screening and with baseline BASDAI > 0 cm and ≥ 4 cm.

Most efficacy endpoints were assessed at week 2 and months 1, 2, 3, 4 and 6; psoriasis, enthesitis, dactylitis, and BASDAI were assessed at months 1, 3, and 6.

All analyses were performed using the Full Analysis Set (FAS), which included all patients who were randomized and received ≥ 1 dose of the study drug. For continuous endpoints for which change from baseline was assessed, a baseline value and ≥ 1 post-baseline value were required for inclusion into the FAS for that endpoint. For endpoints such as psoriasis, enthesitis, dactylitis, or BASDAI, a subset of FAS was used, as there were no mandatory inclusion criteria relating to these endpoints for patients entering these studies, and therefore not all patients presented with the relevant affected domains.

Analyses at month 3 included patients randomized to the tofacitinib and placebo treatment groups only, with data from the two placebo sequences combined. Data for the adalimumab treatment group in OPAL Broaden have been reported previously [20] and are included in the supplementary material (Table S2) for comparison with the pooled analysis reported here; they were not included in the pooled analysis since there was no matching adalimumab group in OPAL Beyond. Analyses after month 3 included the tofacitinib groups only, since patients randomized to the placebo sequences were switched to tofacitinib after month 3; for this same reason, treatment comparisons between each tofacitinib dose and placebo were made at each visit to month 3 only.

For binary endpoints (ACR20/50/70 response rates, HAQ-DI response rate, PASI75 response rate, enthesitis resolution, dactylitis resolution, and BASDAI response rate), the difference in response proportions across studies was estimated using the Cochran–Mantel–Haenszel approach adjusting for study. Large sample approximation was used for statistical testing and for generating 95% confidence intervals (CI). Non-response imputation (NRI) was applied, with missing response treated as non-response.

Changes from baseline in HAQ-DI, painful/tender JC, swollen JC, DLQI, LEI, SPARCC Enthesitis Index, DSS, and BASDAI were analyzed with a mixed model for repeated measures. The model included treatment, visit, treatment-by-visit interaction, geographic region, study and baseline value as fixed effects, and used a common unstructured variance–covariance matrix. Two separate analyses were performed; for analyses to month 3, placebo treatment sequences were combined into a single placebo group (results to month 3 are from this model), whereas for analyses to month 6 (including all post-baseline data to month 6; results after month 3 are from this model), only patients randomized to the tofacitinib groups are included. Missing values were not imputed.

Nominal p values (or two-sided 95% CI) were reported; as this is a post hoc analysis, there was no correction for multiplicity.

Results

Patient Disposition

Of the 710 patients included in this analysis, 316 were from OPAL Broaden and 394 were from OPAL Beyond. Overall, 238, 236, and 236 patients received tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo, respectively (Table 1). An additional 106 patients were randomized to adalimumab in OPAL Broaden, as previously reported [20]. By month 3, 4.6, 4.7, and 8.5% of patients receiving tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo, respectively, discontinued from the studies. Discontinuations were primarily due to adverse events, insufficient clinical response, or patients no longer being willing to participate in the study.

Table 1

Demographics and baseline characteristics; pooled data from OPAL Broaden and OPAL Beyond

	Tofacitinib 5 mg BID (N = 238)	Tofacitinib 10 mg BID (N = 236)	Placebo (N = 236)	Total (N = 710)
Age (years), mean (SD)	49.5 (12.4)	49.4 (11.7)	48.4 (12.5)	49.1 (12.2)
Female, n (%)	121 (50.8)	136 (57.6)	136 (57.6)	393 (55.4)
BMI (kg/m2), mean (SD)	29.8 (6.3)	30.2 (6.3)	29.2 (5.6)	29.7 (6.1)
Race, Caucasiana, n (%)	226 (95.0)	221 (93.6)	222 (94.1)	669 (94.2)
PsA duration (years), mean (SD)	8.6 (7.9)	7.5 (6.6)	8.1 (7.5)	8.0 (7.4)
Tender JCb, mean (SD)	20.5 (12.8)	23.2 (15.8)	20.2 (14.6)	21.3 (14.5)
Swollen JCc, mean (SD)	12.5 (10.3)	12.3 (9.8)	10.9 (8.9)	11.9 (9.7)
hsCRP > 2.87 mg/l, n (%)	153 (64.3)	148 (62.7)	143 (60.6)	444 (62.5)
Polyarticular diseased, n (%)	236 (99.2)	231 (97.9)	229 (97.0)	696 (98.0)
Screening distal interphalangeal joints involvement, n (%)	153 (64.3)	151 (64.0)	134 (56.8)	438 (61.7)
Arthritis mutilans, n (%)	16 (6.7)	18 (7.6)	23 (9.7)	57 (8.0)
Spondylitise, n (%)	50 (21.0)	47 (19.9)	44 (18.6)	141 (19.9)
Psoriatic BSA ≥ 3%, n (%)	162 (68.1)	151 (64.0)	168 (71.2)	481 (67.7)
PASIf, mean (SD)	N1 = 162 9.0 (7.8)	N1 = 151 10.1 (7.9)	N1 = 168 10.3 (9.9)	N1 = 481 9.8 (8.6)
Enthesitis assessed by LEIg, n (%)	158 (66.4)	163 (69.1)	158 (66.9)	479 (67.5)
LEI score (continuous)h, mean (SD)	N1 = 158 2.8 (1.5)	N1 = 163 3.2 (1.7)	N1 = 158 2.8 (1.5)	N1 = 479 2.9 (1.6)
Enthesitis assessed by SPARCCi, n (%)	177 (74.4)	189 (80.1)	179 (75.8)	545 (76.8)
SPARCC Enthesitis Index (continuous)h, mean (SD)	N1 = 177 5.4 (3.7)	N1 = 189 6.1 (4.2)	N1 = 179 5.3 (3.6)	N1 = 545 5.6 (3.9)
Dactylitisj, n (%)	127 (53.4)	125 (53.0)	121 (51.3)	373 (52.5)
DSS score (continuous)h, mean (SD)	N1 = 127 8.4 (9.0)	N1 = 125 9.0 (8.2)	N1 = 121 8.3 (7.3)	N1 = 373 8.6 (8.2)
Baseline BASDAI ≥ 4 cme, n (%)	43 (18.1)	41 (17.4)	38 (16.1)	122 (17.2)
Baseline BASDAIe (cm), mean (SD)	N1 = 50 6.0 (2.0)	N1 = 47 6.3 (2.1)	N1 = 44 6.5 (2.0)	N1 = 141 6.3 (2.0)
Concomitant MTXk, n (%)	186 (78.2)	180 (76.3)	193 (81.8)	559 (78.7)
Corticosteroid usel, n (%)	67 (28.2)	37 (15.7)	49 (20.8)	153 (21.5)
Prior TNFi use, n (%)	131 (55.0)	132 (55.9)	132 (55.9)	395 (55.6)
Prior non-TNFi bDMARDs usem, n (%)	14 (5.9)	18 (7.6)	14 (5.9)	46 (6.5)

Additional characteristics are in Table S1 in the supplementary material

BASDAI Bath Ankylosing Spondylitis Disease Activity Index, bDMARD biologic disease-modifying antirheumatic drug, BID twice daily, BMI body mass index, BSA body surface area, csDMARD conventional synthetic disease-modifying antirheumatic drug, DSS Dactylitis Severity Score, FAS Full Analysis Set, hsCRP high-sensitivity C-reactive protein, JC joint count, LEI Leeds Enthesitis Index, MTX methotrexate, n number of patients meeting criterion, N number of patients in FAS, N1 number of evaluable patients, PASI Psoriasis Area and Severity Index, PsA psoriatic arthritis, SD standard deviation, SPARCC Spondyloarthritis Research Consortium of Canada, TNFi tumor necrosis factor inhibitor

aOthers were black, Asian, and other races

bOut of 68 joints

cOut of 66 joints

d ≥ 5 tender or swollen joints

ePatients with spondylitis (determined by the investigator site’s qualified assessor) at screening

fPatients with baseline BSA ≥ 3% and baseline PASI > 0

gDetermined by baseline LEI > 0

hPatients with baseline score > 0

iDetermined by baseline SPARCC Enthesitis Index > 0

jDetermined by baseline DSS > 0

kMTX only; other patients received csDMARDs including sulfasalazine, leflunomide, and hydroxychloroquine

lOral corticosteroid use at baseline

mIncluded patients who received any non-TNFi bDMARD or both TNFi and non-TNFi bDMARDs; non-TNFi bDMARDs included abatacept, anakinra, guselkumab, ixekizumab, rituximab, secukinumab, tocilizumab, and ustekinumab

Patient Demographics and Baseline Characteristics

The demographics and baseline characteristics of the pooled dataset from OPAL Broaden and OPAL Beyond were comparable between treatment groups (Table 1; Table S1 in the supplementary material). The majority of patients had polyarticular disease (98.0%), psoriasis affecting ≥ 3% BSA (67.7%), enthesitis (80.3%), dactylitis (52.5%), and high-sensitivity C-reactive protein levels above the upper limit of normal (> 2.87 mg/l; 62.5%) at baseline. Of the TNFi-experienced patients, 18.0% and 13.2% had previously failed 2 and ≥ 3 TNFi treatments, respectively. Methotrexate was the concomitant treatment for 78.7% of patients. Patients with an IR to TNFi had longer mean PsA durations vs. TNFi-naïve patients (mean [standard deviation]: 9.4 [7.5] vs. 6.1 [6.5] years). Across the treatment groups, 18.6–21.0% of patients had spondylitis symptoms at screening, and 2.5–2.9% and 16.1–18.1% of patients had baseline BASDAI > 0 to < 4 cm and ≥ 4 cm, respectively.

Peripheral Arthritis

ACR20 (a primary endpoint of each study), ACR50 and ACR70 response rates were higher with tofacitinib 5 and 10 mg BID vs. placebo at month 3 (p ≤ 0.05; Fig. 1). ACR20, ACR50, and ACR70 response rates further improved or were maintained at month 6 (Fig. 2).

Fig. 1

ACR20, ACR50, and ACR70 response rates at month 3; pooled data from OPAL Broaden and OPAL Beyond (FAS, NRI). ACR American College of Rheumatology, BID twice daily, FAS Full Analysis Set, NRI non-response imputation, SE standard error. *p ≤ 0.05; **p < 0.01; ***p < 0.001 vs. placebo; p values are based on large sample approximation to difference in binomial proportions adjusting for study by Cochran–Mantel–Haenszel approach; missing response was imputed as non-response

Fig. 2

ACR20, ACR50, and ACR70 response rates to month 6; pooled data from OPAL Broaden and OPAL Beyond (FAS, NRI). ACR American College of Rheumatology, BID twice daily, FAS Full Analysis Set, NRI non-response imputation, RR response rate in terms of ACR response, SE standard error. *p ≤ 0.05; **p < 0.01; ***p < 0.001 vs. placebo; p values are based on large sample approximation to difference in binomial proportions adjusting for study by Cochran–Mantel–Haenszel approach; p values not calculated beyond month 3 as the placebo-controlled period ended at month 3; missing response was imputed as non-response

Improvement in physical function, assessed by change in HAQ-DI (primary endpoint of each study), was greater at month 3 with tofacitinib 5 and 10 mg BID vs. placebo (p < 0.001, Fig. 3a). A greater proportion of tofacitinib-treated patients achieved a clinically significant HAQ-DI response (decrease from baseline of ≥ 0.35) at month 3 vs. placebo (p < 0.001, Table 2). Improvements in the number of painful/tender and swollen joints were also greater at month 3 with tofacitinib vs. placebo (p < 0.001, Fig. 3b and 3c). Improvements were maintained to month 6.

Fig. 3

LSM change from baseline in HAQ-DI, painful/tender JC and swollen JC, PASI75 response rate and LSM change from baseline in DLQI to month 6; pooled data from OPAL Broaden and OPAL Beyond. BID twice daily, BSA body surface area, CFB change from baseline, DLQI Dermatology Life Quality Index, HAQ-DI Health Assessment Questionnaire-Disability Index, JC joint count, LSM least squares mean, PASI Psoriasis Area and Severity Index, RR response rate in terms of PASI75, SE standard error. *p ≤ 0.05; **p < 0.01; ***p < 0.001 vs. placebo; p values for HAQ-DI, painful/tender JC, swollen JC and DLQI are based on mixed model for repeated measures without imputation for missing values; p values for PASI75 are based on large sample approximation to difference in binomial proportions adjusting for study by Cochran–Mantel–Haenszel approach; missing response was imputed as non-response; p values not calculated beyond month 3 as the placebo-controlled period ended at month 3. aOut of 68 joints; bOut of 66 joints. N for HAQ-DI, painful/tender JC, swollen JC and DLQI is the number of patients evaluable at each visit; N for PASI75 is the number of patients with baseline BSA ≥ 3% and PASI > 0

Table 2

Physical function, enthesitis, dactylitis, and BASDAI endpoints at month 3 and month 6; pooled data from OPAL Broaden and OPAL Beyond (NRI)

	Month 3			Month 6
	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID
HAQ-DI response ratea, n/N (%)	109/212*** (51.4)	101/215*** (47.0)	61/210 (29.1)	119/212 (56.1)	96/215 (44.7)
Enthesitis resolution rate (LEI)b, n/N (%)	58/158** (36.7)	58/163** (35.6)	34/158 (21.5)	75/158 (47.5)	71/163 (43.6)
Enthesitis resolution rate (SPARCC Enthesitis Index)b, n/N (%)	52/177 (29.4)	66/189* (34.9)	42/179 (23.5)	69/177 (39.0)	76/189 (40.2)
Dactylitis resolution rate (DSS)b, n/N (%)	55/127* (43.3)	69/125*** (55.2)	37/121 (30.6)	71/127 (55.9)	76/125 (60.8)
BASDAI response ratec, n/N (%)	16/43* (37.2)	12/41 (29.3)	6/38 (15.8)	16/43 (37.2)	10/41 (24.4)

BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BID twice daily, DSS Dactylitis Severity Score, HAQ-DI Health Assessment Questionnaire-Disability Index, LEI Leeds Enthesitis Index, n number of patients with response, N number of patients in the Full Analysis Set meeting baseline endpoint-specific criteria, NRI non-response imputation, SPARCC Spondyloarthritis Research Consortium of Canada

*p ≤ 0.05; **p < 0.01; ***p < 0.001 vs. placebo at month 3; p values are based on large sample approximation to difference in binomial proportions adjusting for study by Cochran–Mantel–Haenszel approach; p values not calculated at month 6 as the placebo-controlled period ended at month 3; missing response was imputed as non-response

aDecrease from baseline of ≥ 0.35 in HAQ-DI among patients with baseline HAQ-DI ≥ 0.35

bIndicated by post-baseline score = 0 in patients with baseline score > 0

cBASDAI < 4 cm among patients with spondylitis at screening and baseline BASDAI ≥ 4 cm

Psoriasis

A greater proportion of patients receiving tofacitinib 5 and 10 mg BID achieved PASI75 vs. placebo at month 3 (p < 0.001; Fig. 3d); PASI75 response further improved at month 6. PASI75 response was numerically greater in patients receiving tofacitinib 10 vs. 5 mg BID. Patients receiving tofacitinib also achieved greater improvements in DLQI at month 3 vs. those receiving placebo (p < 0.001; Fig. 3e), and greater improvements with tofacitinib 10 vs. 5 mg BID, with improvements increased or maintained at month 6.

Enthesitis and Dactylitis

Changes in LEI and SPARCC Enthesitis Index were greater at month 3 for both tofacitinib doses vs. placebo (p < 0.01; Fig. 4a, b). A higher proportion of tofacitinib-treated patients achieved enthesitis resolution at month 3, as measured by the LEI and SPARCC Enthesitis Index, vs. placebo (p ≤ 0.05 except for tofacitinib 5 mg BID for SPARCC Enthesitis Index; Table 2). Further improvements in all enthesitis endpoints were seen at month 6.

Fig. 4

LSM change from baseline in LEI, SPARCC Enthesitis Index, DSS and BASDAI to month 6; pooled data from OPAL Broaden and OPAL Beyond. BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BID twice daily, CFB change from baseline, DSS Dactylitis Severity Score, LEI Leeds Enthesitis Index, LSM least squares mean, N number of patients evaluable at each visit, SE standard error, SPARCC Spondyloarthritis Research Consortium of Canada. *p ≤ 0.05; **p < 0.01; ***p < 0.001 vs. placebo; p values are based on mixed model for repeated measures without imputation for missing values; p values not calculated beyond month 3 as the placebo-controlled period ended at month 3. aPatients with baseline score > 0; bPatients with spondylitis (as determined by the investigator site’s qualified assessor) at screening and baseline BASDAI > 0 cm; cPatients with spondylitis (as determined by the investigator site’s qualified assessor) at screening and baseline BASDAI ≥ 4 cm

The change in DSS, and the proportion of patients who achieved dactylitis resolution, were greater for tofacitinib vs. placebo at month 3 (p ≤ 0.05; Fig. 4c, Table 2). Further improvements in both dactylitis endpoints were seen at month 6.

BASDAI

In patients determined by the investigator as having spondylitis (although imaging was not mandated) at screening and baseline BASDAI > 0 cm or ≥ 4 cm, changes in BASDAI at month 3 were greater vs. placebo with tofacitinib 10 mg BID (p ≤ 0.05; Fig. 4d, e). BASDAI response rates were also greater vs. placebo with tofacitinib 5 mg BID at month 3 (p ≤ 0.05; Table 2). Improvements were maintained at month 6 with both tofacitinib doses.

Comparison with Findings from Primary Studies

Endpoints for OPAL Broaden and OPAL Beyond are shown in detail in Table S2 in the supplementary material, reporting both nominal significance vs. placebo and significance vs. placebo under type 1 error control. ACR20, ACR50, and HAQ-DI response rates, and changes in HAQ-DI and swollen JC showed significant improvement (p ≤ 0.05) at month 3 with both doses of tofacitinib vs. placebo in the pooled dataset and in both the individual OPAL Broaden and OPAL Beyond studies (significance under type 1 error control for ACR20 and ACR50 response rates, and change in HAQ-DI in both individual studies). ACR70 response rates (significance under type 1 error control for both tofacitinib doses in OPAL Broaden), PASI75 response rates (significance under type 1 error control with both tofacitinib doses in OPAL Broaden and tofacitinib 10 mg BID in OPAL Beyond), enthesitis (significance under type 1 error control for change in LEI with tofacitinib 10 mg BID in OPAL Broaden), dactylitis and change in painful/tender JC at month 3 reached statistical significance (p ≤ 0.05) with both doses vs. placebo in the pooled analysis, and with at least one dose in at least one of the individual studies.

Discussion

This post hoc analysis of pooled data from two phase 3 studies of tofacitinib in patients with active PsA explored the efficacy of tofacitinib over 6 months of treatment. Patients included those who were naïve to TNFi treatment (OPAL Broaden) and those with an IR to TNFi (OPAL Beyond), 13.2% of whom had received ≥ 3 TNFi treatments; all were receiving one background csDMARD. Pooling has the benefit of increasing the sample size to obtain more precise estimates of the efficacy of a treatment, even in a population with mixed treatment history, especially for endpoints for disease manifestations that do not affect all patients. Furthermore, these results are particularly robust, as NRI was used in the analysis of binary endpoints; missing responses were imputed as non-responses, thus providing conservative estimates of response to treatment. The results of the pooled analyses are not intended to supersede any of the results of the pre-specified analyses in the individual studies; indeed, some efficacy outcomes, such as ACR response rates, tended to be lower for TNFi-IR patients in OPAL Beyond compared with TNFi-naïve patients in OPAL Broaden [20, 21].

ACR20 responses with both tofacitinib doses at month 3 (50.0–53.0%) and month 6 (57.2–59.2%) were generally comparable with those reported for the adalimumab control in OPAL Broaden (51.9% at month 3 and 64.2% at month 6) [20], as well as biologic DMARD and TNFi treatments for mixed populations of TNFi-naïve and experienced patients in published studies (43.8–63.8% across 3 and 6 months) [8, 9, 11, 12, 24].

Physical function significantly improved (p ≤ 0.05) with both doses of tofacitinib vs. placebo at month 3 (change in HAQ-DI: − 0.38 vs. − 0.16), as did the change in the number of painful/tender (− 9.6 to − 10.4 vs. − 5.8) and swollen joints (− 7.2 vs. − 3.7). At month 3 and month 6, 44.7–56.1% of the tofacitinib-treated patients achieved clinically relevant improvements in HAQ-DI (decrease from baseline in HAQ-DI ≥ 0.35). Additionally, a significantly greater proportion of tofacitinib-treated patients achieved PASI75 response at month 3 vs. placebo (32.1–43.7% vs. 14.3%; p ≤ 0.05); this increased to month 6. Patients who received tofacitinib also experienced a significant (p ≤ 0.05) decrease from baseline in DLQI at month 3 vs. placebo, indicating improvements in quality of life (which was numerically greater with tofacitinib 10 vs. 5 mg BID); this was maintained to month 6. Improvements in enthesitis, dactylitis, and BASDAI scores with tofacitinib treatment vs. placebo were also observed at month 3. The proportions of patients receiving tofacitinib 5 and 10 mg BID at month 6 who achieved enthesitis (based on LEI and SPARCC) and dactylitis resolution were 39.0–47.5% and 55.9–60.8%, respectively. The resolution of these clinical manifestations, which are associated with increased disease burden of PsA [25], is of particular importance as treatment options for these are limited [26, 27]. Overall, a significant proportion of patients achieved ACR20, ACR50, ACR70, PASI75, and HAQ-DI responses, and improvements in enthesitis, dactylitis, and BASDAI scores were observed over time, indicating that tofacitinib treatment provides clinically meaningful improvements in the disease outcomes of PsA. There were no observed differences between the efficacy of tofacitinib 5 and 10 mg BID in the peripheral arthritis, dactylitis, and enthesitis domains; however, rates of PASI75 and improvements in DLQI appeared to be greater with tofacitinib 10 vs. 5 mg BID. While we report results for tofacitinib vs. placebo across multiple clinical outcomes, due to the heterogeneity of clinical manifestations of PsA, composite outcome measures assessing efficacy across the multiple domains of PsA in one single instrument may prove useful in future clinical trials [28].

Comparisons with the individual results from OPAL Broaden and OPAL Beyond showed generally consistent findings with this pooled analysis (Table S2 in the supplementary material), with ACR20, ACR50, and HAQ-DI response rates, changes in HAQ-DI and swollen JC significantly greater with tofacitinib vs. placebo in both individual studies and the pooled dataset. PASI75, enthesitis, dactylitis, and BASDAI endpoints represented PsA domains that were present at baseline for only a subgroup of the study populations and were therefore undersized for the statistical analysis of the individual studies; however, pooling the datasets increased the sample size to improve the precision of the effect estimates and revealed a difference between tofacitinib and placebo at month 3. In the pooled analysis, significant differences were observed in ACR70 response rates, PASI75 response rates and changes in painful/tender JC, LEI and DSS (p ≤ 0.05) vs. placebo at month 3 with both tofacitinib doses; these were significant in at least one of the individual phase 3 studies, but were not significant with both tofacitinib doses in both phase 3 studies. Changes in BASDAI in patients assessed as having spondylitis at screening (imaging was not required to confirm the presence of spondylitis) and baseline BASDAI > 0 cm and ≥ 4 cm were only significant at month 3 with tofacitinib 10 mg BID vs. placebo in the pooled analysis and OPAL Broaden (baseline BASDAI > 0 cm only; p ≤ 0.05).

This analysis has a number of limitations. Although most of the pooled analyses were pre-specified prior to unblinding of data, this was considered to be a post hoc analysis; OPAL Broaden and OPAL Beyond were designed to include study populations with distinctly different treatment histories, and therefore comparisons between the pooled analysis and the individual studies must be made with caution. Furthermore, comparisons with placebo were limited to the 3-month placebo-controlled portion of the phase 3 studies, and there was no stratification for background use of methotrexate [29]. Axial symptoms were assessed using BASDAI, but axial involvement was not an inclusion criterion for the studies nor were rigorous diagnostic criteria defined in the protocols (imaging was not performed); a limited number of patients with axial symptoms were identified by qualified assessors at investigational sites. Additionally, with respect to the statistical analyses, p values were generated with no correction for multiplicity. Finally, this analysis focuses on the efficacy of tofacitinib in treating PsA; safety data are reported in the primary manuscripts [20, 21] as well as in a pooled safety analysis [30]. No new safety risks were identified in an interim analysis of data from patients with active PsA receiving tofacitinib for up to 36 months in the ongoing LTE study, OPAL Balance (NCT01976364; data-cut: November 2017; database not locked; data may change) [31].

Conclusions

In conclusion, in a pooled analysis of two PsA phase 3 trials of TNFi-naïve patients with an IR to csDMARDs and patients with an IR to TNFi, tofacitinib 5 and 10 mg BID showed greater improvements vs. placebo at month 3 across four PsA disease domains: peripheral arthritis (including physical function), psoriasis, enthesitis and dactylitis, with efficacy maintained or improved at month 6.

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 33 kb)